Conversely, introducing a drug-resistant SHP2 mutant into tumor cells did not elevate MHC class I levels when treated with SHP099, confirming that the heightened IFNγ signaling induced by SHP099 in cancer cells is directly attributable to the targeted inhibition of SHP2. This evidence concerns the gene IFNG and neoplasm.